Form 8-K - Current report:
SEC Accession No. 0001641172-25-015654
Filing Date
2025-06-18
Accepted
2025-06-18 17:29:55
Documents
19
Period of Report
2025-06-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 46116
2 EX-4.1 ex4-1.htm EX-4.1 128591
3 EX-4.2 ex4-2.htm EX-4.2 122833
4 EX-4.3 ex4-3.htm EX-4.3 129165
5 EX-10.1 ex10-1.htm EX-10.1 260806
6 EX-99.1 ex99-1.htm EX-99.1 14599
7 GRAPHIC ex99-1_001.jpg GRAPHIC 2943
  Complete submission text file 0001641172-25-015654.txt   1019251

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE pcsa-20250617.xsd EX-101.SCH 3056
9 XBRL LABEL FILE pcsa-20250617_lab.xml EX-101.LAB 34239
10 XBRL PRESENTATION FILE pcsa-20250617_pre.xml EX-101.PRE 22386
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3697
Mailing Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076
Business Address 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 443-776-3133
Processa Pharmaceuticals, Inc. (Filer) CIK: 0001533743 (see all company filings)

EIN.: 451539785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39531 | Film No.: 251057959
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)